Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma

Advanced Biliary Tract Adenocarcinoma Clinical Trial

Official title: Phase II Study of Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma: Multicenter, Multinational Study

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether sunitinib as second-line treatment in advanced biliary tract carcinoma

Clinical Trial Description

Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: multicenter, multinational study ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenocarcinoma
• Advanced Biliary Tract Adenocarcinoma

• NCT number: NCT01082809
• Study type: Interventional
• Source: Samsung Medical Center
• Status: Completed
• Phase: Phase 2
• Start date: March 2009
• Completion date: February 2012